GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1Results posted

A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

Comparative Pharmacokinetics of Dulaglutide After Administration Via an Auto-injector and a Manual Syringe in Healthy Subjects

Lead sponsor

Eli Lilly and Company

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-32•Healthy volunteers

Primary endpoints

•Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide•Cmax for Dulaglutide

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01524770

Org study ID14142

Secondary IDH9X-MC-GBDTEli Lilly and Company

Timeline

Milestones

Study first posted2012-02-02estimated

Last update posted2014-10-22estimated

Results first posted2014-10-22estimated

Study start2012-03 (month precision)

Primary completion2012-06actual (month precision)

Study completion2012-06actual (month precision)

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy males or females, as determined by medical history and physical examination

•Male participants with female partners of child-bearing potential or partners who are pregnant or breastfeeding agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator

•The method may be one of the following:

–condom with spermicidal agent

–male participant sterilization

–true abstinence (which is in line with the participant's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable)

•Female participants not of child-bearing potential (that is, are postmenopausal or permanently sterilized [such as, tubal occlusion, hysterectomy, bilateral salpingectomy, bilateral oophorectomy]). Such participants will not be required to use contraception but must test negative for pregnancy at the time of enrollment

•Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) or spontaneous amenorrhea for 6 to 12 months, with follicle stimulating hormone (FSH) ≥40 milli-international units per milliliters (mIU/mL)

•Female participants who have undergone sterilization by tubal ligation agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such participants must also test negative for pregnancy at the time of enrollment

•Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meters squared (kg/m^2), inclusive, at screening

•Have clinical laboratory test results within the normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator

•Have venous access sufficient to allow for blood sampling as per the protocol

•Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures and are willing to follow study restrictions

•Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site

Exclusion criteria

•Are currently enrolled in or have completed or discontinued within the last 30 days from a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study

•Have known allergies to Glucagon-like peptide 1 (GLP-1) -related compounds including dulaglutide, or any components of the formulation

•Are persons who have previously completed or withdrawn from this study or any other study investigating dulaglutide in the 3 months prior to screening or have received glucagon-like peptides or incretin mimetics in the 3 months prior to screening

•Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study

•Have an abnormal blood pressure (after at least 5 minutes sitting) that, in the opinion of the investigator, increases the risks associated with participating in the study

•Have a history or presence of cardiovascular, respiratory, hepatic, renal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data

•Have a history or presence of pancreatitis (history of chronic pancreatitis or idiopathic acute pancreatitis) or gastrointestinal disorder, for example relevant esophageal reflux or gall bladder disease, or any gastrointestinal disease which impacts gastric emptying (such as, gastric bypass surgery, pyloric stenosis, with the exception of appendectomy) or could be aggravated by GLP-1 analogs. Participants with dyslipidemia, and participants who had cholecystolithiasis (removal of gall stones) and/or cholecystectomy (removal of gall bladder) in the past, with no further sequelae, may be included in the study at the discretion of the screening physician

•Show evidence of significant active neuropsychiatric disease

•Have family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC

•Regularly use known drugs of abuse and/or show positive findings on urinary drug screening

•Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies

•Show evidence of hepatitis C and/or positive hepatitis C antibody

•Show evidence of hepatitis B and/or positive hepatitis B surface antigen

•Are women with a positive pregnancy test or women who are lactating

•Have used or intend to use over-the-counter medication other than acetaminophen within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy [HRT]) within 14 days prior to dosing

•Have donated blood of more than 500 milliliters (mL) within the last month

•Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to adhere to the alcohol restrictions (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)

•Smoke more than 10 cigarettes (or equivalent in nicotine) per day, and are unwilling to refrain from smoking on the day of dulaglutide administration or are unable to abide by clinical research unit (CRU) restrictions

•In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

6 endpoints

Primary/registry result

Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide

Time frame:Predose to 336 hours postdose

AUC₀–∞

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms times hours per milliliters	95% CI
Auto-injector	14700	—
Manual Syringe	14300	—

Primary/registry result

Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide

Time frame:Predose to 336 hours postdose

Cmax

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms per milliliter (ng/mL)	95% CI
Auto-injector	91.1	—
Manual Syringe	88.2	—

Primary/protocol endpoint

Pharmacokinetics: Area Under the Concentration Curve (AUC[0-336]) for Dulaglutide

Time frame:Predose to 336 hours postdose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Pharmacokinetics: Maximum Concentration (Cmax) for Dulaglutide

Time frame:Predose to 336 hours postdose

Cmax

concentration, descriptive

Secondary/registry result

Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide

Time frame:Predose to 336 hours postdose

Tmax

descriptive

Posted result

Group	Value (median), hours	95% CI
Auto-injector	48.0	24.0 – 96.0
Manual Syringe	48.0	24.0 – 96.0

Secondary/protocol endpoint

Pharmacokinetics: Time to Maximum Concentration (Tmax) for Dulaglutide

Time frame:Predose to 336 hours postdose

Tmax

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.